OBJECTIVE: Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in terms of radiographically evident quantitative lung involvement. We undertook this study to assess the impact of TCZ on lung function preservation in a post hoc analysis, stratifying treatment arms according to the degree of lung involvement. METHODS: The focuSSced trial was a phase III randomized placebo-controlled trial of TCZ in patients with SSc and progressive skin disease. Participants underwent baseline and serial spirometry along with high-resolution chest computed tomography at baseline and at week 48. Quantitative interstitial lung disease (QILD) and fibrosis scores were assessed by computer software. We classified QILD into the following categories of lung involvement: mild (>5-10%), moderate (>10-20%), and severe (>20%). RESULTS: Of 210 participants recruited for the trial, 136 patients (65%) had ILD. The majority of these patients (77%) had moderate-to-severe involvement (defined as >10% lung involvement). The TCZ arm demonstrated preservation of forced vital capacity percent predicted (FVC%) over 48 weeks (least squares mean change in FVC% = -0.1) compared to placebo (-6.3%). For mild, moderate, and severe QILD, the mean ± SD change in FVC% in the TCZ arm at 48 weeks were -4.1 ± 2.5% (n = 11), 0.7 ± 1.9% (n =19), and 2.1 ± 1.6% (n = 26), respectively, and in the placebo group were -10.0 ± 2.6% (n = 11), -5.7 ± 1.6% (n = 26), and -6.7 ± 2.0% (n = 16), respectively. Similar treatment-related preservation findings were seen independent of fibrosis severity. CONCLUSION: TCZ in early SSc-associated ILD with progressive skin disease stabilized FVC% over 48 weeks, independent of the extent of radiographically evident QILD.
OBJECTIVE: Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in terms of radiographically evident quantitative lung involvement. We undertook this study to assess the impact of TCZ on lung function preservation in a post hoc analysis, stratifying treatment arms according to the degree of lung involvement. METHODS: The focuSSced trial was a phase III randomized placebo-controlled trial of TCZ in patients with SSc and progressive skin disease. Participants underwent baseline and serial spirometry along with high-resolution chest computed tomography at baseline and at week 48. Quantitative interstitial lung disease (QILD) and fibrosis scores were assessed by computer software. We classified QILD into the following categories of lung involvement: mild (>5-10%), moderate (>10-20%), and severe (>20%). RESULTS: Of 210 participants recruited for the trial, 136 patients (65%) had ILD. The majority of these patients (77%) had moderate-to-severe involvement (defined as >10% lung involvement). The TCZ arm demonstrated preservation of forced vital capacity percent predicted (FVC%) over 48 weeks (least squares mean change in FVC% = -0.1) compared to placebo (-6.3%). For mild, moderate, and severe QILD, the mean ± SD change in FVC% in the TCZ arm at 48 weeks were -4.1 ± 2.5% (n = 11), 0.7 ± 1.9% (n =19), and 2.1 ± 1.6% (n = 26), respectively, and in the placebo group were -10.0 ± 2.6% (n = 11), -5.7 ± 1.6% (n = 26), and -6.7 ± 2.0% (n = 16), respectively. Similar treatment-related preservation findings were seen independent of fibrosis severity. CONCLUSION: TCZ in early SSc-associated ILD with progressive skin disease stabilized FVC% over 48 weeks, independent of the extent of radiographically evident QILD.
Authors: Yossra A Suliman; Rucsandra Dobrota; Dörte Huscher; Thi D L Nguyen-Kim; Britta Maurer; Suzana Jordan; Rudolf Speich; Thomas Frauenfelder; Oliver Distler Journal: Arthritis Rheumatol Date: 2015-12 Impact factor: 10.995
Authors: Jonathan G Goldin; Grace Hyun J Kim; Chi-Hong Tseng; Elizabeth Volkmann; Daniel Furst; Philip Clements; Matt Brown; Michael Roth; Dinesh Khanna; Donald P Tashkin Journal: Ann Am Thorac Soc Date: 2018-11
Authors: Tiffany A Winstone; Deborah Assayag; Pearce G Wilcox; James V Dunne; Cameron J Hague; Jonathon Leipsic; Harold R Collard; Christopher J Ryerson Journal: Chest Date: 2014-08 Impact factor: 9.410
Authors: Yannick Allanore; Robert Simms; Oliver Distler; Maria Trojanowska; Janet Pope; Christopher P Denton; John Varga Journal: Nat Rev Dis Primers Date: 2015-04-23 Impact factor: 52.329
Authors: Nicole S L Goh; Sujal R Desai; Srihari Veeraraghavan; David M Hansell; Susan J Copley; Toby M Maher; Tamera J Corte; Clare R Sander; Jonathan Ratoff; Anand Devaraj; Gracijela Bozovic; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2008-03-27 Impact factor: 21.405
Authors: Svetlana I Nihtyanova; Benjamin E Schreiber; Voon H Ong; Daniel Rosenberg; Pia Moinzadeh; J Gerrard Coghlan; Athol U Wells; Christopher P Denton Journal: Arthritis Rheumatol Date: 2014-06 Impact factor: 10.995
Authors: Shervin Assassi; Astrud L Leyva; Maureen D Mayes; Roozbeh Sharif; Deepthi K Nair; Michael Fischbach; Ngan Nguyen; John D Reveille; Emilio B Gonzalez; Terry A McNearney Journal: PLoS One Date: 2011-10-14 Impact factor: 3.240
Authors: Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni Journal: Pharmaceuticals (Basel) Date: 2021-04-23
Authors: Elana J Bernstein; Shervin Assassi; Flavia V Castelino; Lorinda Chung; Chase Correia; Luke B Evnin; Tracy M Frech; Jessica K Gordon; Brian A Skaug; Faye N Hant; Laura K Hummers; Nora Sandorfi; Ami A Shah; Victoria K Shanmugam; Virginia D Steen; Dinesh Khanna Journal: ACR Open Rheumatol Date: 2022-04-23
Authors: Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny Journal: Transplant Cell Ther Date: 2021-06-10
Authors: Dinesh Khanna; Alain Lescoat; David Roofeh; Elana J Bernstein; Ella A Kazerooni; Michael D Roth; Fernando Martinez; Kevin R Flaherty; Christopher P Denton Journal: Arthritis Rheumatol Date: 2021-11-10 Impact factor: 15.483